Vyne Therapeutics Inc (VYNE)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
David Domzalski
Employees:
30
520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
800-775-7936

VYNE Therapeutics Inc. focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the. treatment of moderate-to-severe acne vulgaris. FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial. for mild to moderate atopic dermatitis, is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor.

Data derived from most recent annual or quarterly report
Market Cap 13.251 Million Shares Outstanding3.28 Million Avg 30-day Volume 8.171 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.63
Price to Revenue32.9813 Debt to Equity0.0 EBITDA-32.637 Million
Price to Book Value0.7772 Operating Margin-8233.4152 Enterprise Value-7.278 Million
Current Ratio3.602 EPS Growth0.059 Quick Ratio3.274
1 Yr BETA 7.169 52-week High/Low 8.73 / 1.99 Profit Margin-8620.1474
Operating Cash Flow Growth39.7898 Free Cash Flow to Firm (FCFF) TTM -14.485 Million Free Cash Flow to Equity (FCFE) TTM-23.457 Million
Altman Z-Score-40.5178

Are you looking for this stock instead?

View SEC Filings from VYNE instead.

View recent insider trading info

Vyne Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding VYNE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding VYNE

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-07-05 by ZERONDA TYLER
  • 4: filed on 2023-07-05 by STUART IAIN
  • 4: filed on 2023-07-05 by HARSCH MUTYA
  • 4: filed on 2023-07-05 by DOMZALSKI DAVID
  • 4: filed on 2023-06-02 by HARSCH MUTYA
  • 4: filed on 2023-06-02 by DOMZALSKI DAVID
  • 4: filed on 2023-04-04 by ZERONDA TYLER
  • 4: filed on 2023-04-04 by HARSCH MUTYA
  • 4: filed on 2023-03-22 by LEPORE PATRICK G
  • 4: filed on 2023-03-22 by HARSCH MUTYA

    • Events (8k)

  • 8-K: filed on 2023-08-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-11:
    Item 2.02: Results of Operations and Financial Condition
  • 8-K: filed on 2023-05-01:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-28:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-17:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-30:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 8.01: Other Events
  • 8-K: filed on 2022-08-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    STUART IAIN CHIEF SCIENTIFIC OFFICER

    • Officer
    		 10,239 2023-06-30 3

    DOMZALSKI DAVID PRESIDENT AND CEO

    • Officer
    • Director
    		 52,433 2023-06-30 5

    HARSCH MUTYA CHIEF LEGAL OFFICER AND GC

    • Officer
    		 25,750 2023-06-30 5

    ZERONDA TYLER CHIEF FINANCIAL OFFICER

    • Officer
    		 8,017 2023-06-30 3

    LEPORE PATRICK G

    • Director
    		 23,472 2023-03-20 1

    BARBARI SHARON

    • Director
    		 20,500 2022-08-10 0

    BRUNO ANTHONY D

    • Director
    		 20,500 2022-08-10 0

    BASTA STEVEN L

    • Director
    		 20,500 2022-08-10 0

    SANDOVAL ELISABETH

    • Director
    		 20,500 2022-08-10 0

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    EDELMAN JOSEPH

    • 10% Owner
    		 4,935,057 2021-08-16 0

    BRIGHT REX

    • Director
    		 20,500 2021-07-19 0

    WILEY MATTHEW T. CHIEF COMMERCIAL OFFICER

    • Officer
    		 109,246 2021-06-30 0

    SAIK ANDREW CHIEF FINANCIAL OFFICER

    • Officer
    		 116,468 2021-05-28 0

    HIRSCH STANLEY

    • Director
    		 660,126 2020-04-03 0

    HADAR ILAN CFO AND COUNTRY MANAGER

    • Officer
    		 0 2020-03-09 0

    BALL KRISTINE M SEE REMARKS

    • Officer
    		 52,534 2019-12-11 0

    KRASNOW RONALD A. SEE REMARKS

    • Officer
    		 15,819 2019-12-11 0

    KWON PAUL CHIEF SCIENTIFIC OFFICER

    • Officer
    		 52,534 2019-12-11 0

    BERNS PAUL L

    • Director
    		 0 2019-06-25 0

    MCGIRR DAVID W J

    • Director
    		 0 2019-06-25 0

    WHITCUP SCOTT M

    • Director
    		 0 2019-06-25 0

    ROYSTON AARON

    • Director
    		 0 2019-06-25 0

    EBEL TED

    • Director
    		 0 2019-06-25 0

    SPELLMAN MARY CHIEF MEDICAL OFFICER

    • Officer
    		 0 2018-12-10 0

    PRESIDIO PARTNERS 2007 GP, L.P.

    PRESIDIO PARTNERS 2007 (PARALLEL), L.P.

    PRESIDIO PARTNERS 2007, L.P.

    COLLIER DAVID J

    WATSON JAMES F

    SOHAIL FAYSAL A.

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    		 No longer subject to file 2018-07-24 0

    FMR LLC

    • SEE REMARK 1
    		 No longer subject to file 2018-01-29 0

    CHA ALBERT

    • Director
    		 4,011,236 2018-01-25 0

    VIVO CAPITAL VIII, LLC

    VIVO CAPITAL SURPLUS FUND VIII, L.P.

    VIVO CAPITAL FUND VIII, L.P.

    • 10% Owner
    		 4,011,236 2018-01-25 0

    REMEDITEX VENTURES LLC

    • 10% Owner
    		 2,761,663 2018-01-25 0

    VENBIO GLOBAL STRATEGIC FUND II L.P.

    • 10% Owner
    		 No longer subject to file 2018-01-25 0

    MERCK & CO., INC.

    MERCK SHARP & DOHME CORP.

    • 10% Owner
    		 1,243,168 2018-01-24 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    VYNE THERAPEUTICS INC VYNE 2023-09-29 22:15:03 UTC -39.3425 44.6625 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 21:45:04 UTC -39.3425 44.6625 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 21:15:03 UTC -39.3425 44.6625 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 20:45:05 UTC -39.3425 44.6625 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 20:15:04 UTC -39.3425 44.6625 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 19:45:04 UTC -39.3425 44.6625 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 19:15:03 UTC 0.0 0.0 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 18:45:03 UTC 0.0 0.0 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 18:15:03 UTC 0.0 0.0 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 17:45:03 UTC 0.0 0.0 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 17:15:04 UTC 0.0 0.0 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 16:45:04 UTC -39.3425 44.6625 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 16:15:03 UTC -39.3425 44.6625 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 15:45:04 UTC -39.3425 44.6625 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 15:15:04 UTC -39.3425 44.6625 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 14:45:04 UTC -39.3425 44.6625 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 14:15:04 UTC -39.3425 44.6625 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 13:45:03 UTC -37.9721 43.2921 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 13:15:04 UTC -37.9721 43.2921 25000
    VYNE THERAPEUTICS INC VYNE 2023-09-29 12:45:05 UTC -37.9721 43.2921 25000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments